Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vasopressin v1a antagonists

A c-r12, alkyl technology, applied in the field of vasopressin V1a antagonists, can solve problems such as no reported activity of V antagonists

Inactive Publication Date: 2009-10-21
VANTIA
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Not reported V 1a antagonist activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vasopressin v1a antagonists
  • Vasopressin v1a antagonists
  • Vasopressin v1a antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0125] Use the following abbreviations:

[0126] AIBN 2,2′-Azobisisobutyronitrile

[0127] Boc tert-butyl carboxylate or tert-butoxycarbonylamino

[0128] Bu butyl-alkyl residues can be further expressed as n (positive, that is, straight chain), i (iso)

[0129] And t (uncle)

[0130] DIEA N, N-Diisopropylethylamine

[0131] DMAP 4-(dimethylamino)pyridine

[0132] DMF Dimethylformamide

[0133] Et ethyl

[0134] EtOAc ethyl acetate

[0135] HOBt 1-Hydroxybenzotriazole

[0136] HPLC high performance liquid chromatography

[0137] H hour(s)

[0138] Me methyl

[0139] Min minute(s)

[0140] MS mass spectrometry

[0141] NMR nuclear magnetic resonance spectroscopy-unless otherwise indicated, NMR spectra are recorded in CDCl3,

[0142] The frequency is 270MHz

[0143] OVA Ornithine Pressor Oxytocin Analog

[0144] Petroleum ether with a boiling point of 60-80℃

[0145] Ph phenyl

[0146] Pn pentyl

[0147] Pr propyl

[0148] THF Tetrahydrofuran

[0149] Tos toluene-4-sulfon...

Embodiment E1

[0154] 6-Chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene

Embodiment E11

[0156] 5-(4-Chloro-2-nitro-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester.

[0157] Add sodium hydride (60% dispersion in oil, 7.28g, 180mmol) to ethyl 5-amino-1-methylpyrazole-4-carboxylate (21.8g, 148mmol) in portions at 0°C. Solution in anhydrous THF. The mixture was allowed to warm to room temperature and stirred for 1 h. A solution of 4-chloro-2-fluoronitrobenzene (22.6 g, 129 mmol) in dry THF (50 ml) was added dropwise. The obtained dark purple solution was stirred at room temperature for 18h and then poured into ice-cold 1N hydrochloric acid. The obtained mixture was extracted with dichloromethane (200 ml×2), and the combined organic extracts were washed with brine and concentrated in vacuo. The residue was purified by flash silica gel chromatography (eluent; 60% petroleum ether: 40% EtOAc) to obtain the title compound (27.5 g, 62%).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns compounds according to general formula 1a . Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of primary dysmenorrhoea.

Description

Invention field [0001] The present invention relates to compounds having vasopressin Via antagonist activity and pharmaceutical compositions containing these compounds. The invention also relates to vasopressin V 1a The use of antagonists in the treatment of certain physiological disorders such as Raynaud's disease and dysmenorrhea (primary dysmenorrhea and / or secondary dysmenorrhea). [0002] Priority is claimed for EP Patent Application No. 04104062 and US Patent Application No. 60 / 603557 filed on August 24, 2004. Background technique [0003] Nerve growth hormone (neurophyseal hormone) vasopressin (VP) and oxytocin (OT) are cyclic nonapeptides secreted by the posterior pituitary gland. [0004] Only one OT receptor has been fully characterized so far, while three VP receptors are known. These are named V 1a , V 1b And V 2 Receptor. [0005] Vasopressin acts on blood vessels, where it is an effective vasoconstrictor, and acts on the kidneys where it promotes water reuptake, lea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04C07D417/10C07D267/14C07D231/38C07D265/36C07D231/42C07D215/08C07D267/16C07D498/14C07D333/44C07D513/14A61K31/55A61K31/5517A61K31/495A61K31/553A61K31/38C07D223/16
CPCC07D223/16C07D231/42C07D413/14C07D267/16C07D498/14C07D265/36C07D513/04C07D513/14C07D295/088C07D487/04C07D215/08C07D333/44C07D417/10C07D267/14A61P1/08A61P1/16A61P15/00A61P15/04A61P15/06A61P15/08A61P23/00A61P25/00A61P25/14A61P25/22A61P25/24A61P3/00A61P3/12A61P35/00A61P3/06A61P43/00A61P7/00A61P7/10A61P9/00A61P9/04A61P9/12C07D233/16A61K31/495
Inventor R·B·安杰伊A·J·巴克斯特C·希尼M·L·斯托克利M·布里安罗P·赫德森R·汉迪
Owner VANTIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com